Patients who receive the Global Initiative for Asthma (GINA) Step 4/5 therapy incur significantly greater direct and indirect healthcare and productivity costs than patients who do not receive GINA 4/5 asthma therapy.
The initiation of metformin therapy was associated with a lower risk for asthma exacerbations.
Despite its prevalence, many myths surround asthma. We debunk 5 common misconceptions your patients might have.
Home-based pulmonary rehabilitation improves long-term exercise tolerance and quality of life in patients with severe asthma.
Allergy immunotherapy is associated with a decreased risk for asthma progression, particularly in younger patients.
The FDA has approved Nucala as an add-on maintenance treatment for patients 6 to 11 years old with severe eosinophilic asthma.
Military personnel deployed to Afghanistan and Southwest Asia experience a complex mixture of exposures, most notably PM2.5 from desert dust, which can lead to adverse respiratory effects.
Among patients with aspirin-exacerbated respiratory disease, there appears to be a gradual progression from asthma to nasal polyps and then to aspirin sensitivity.
In patients with mild asthma, once-daily fluticasone furoate significantly improved bronchoprotection after a single dose during the course of a week.
Children with severe asthma have greater prebronchodilator airflow obstruction and bronchodilator reversibility than children with nonsevere asthma.
